# REMI Platform for Remote EEG Monitoring

> **NIH NIH SB1** · EPITEL, INC. · 2024 · $1,199,931

## Abstract

ABSTRACT
REMI Platform for Remote EEG Monitoring
The REMI EEG screening platform. The REMI app running on a medical tablet guides staff through the
placement of four Epilog sensors. Epilog transmits EEG through Bluetooth to the app which then relays the
data to a cloud server running Persyst EEG reviewing software. An epileptologist logs on to Persyst Mobile to
remotely review Epilog EEG in real time as a 10-channel “longitudinal-transverse” montage in Persyst.
PROBLEM There is a clear need for discrete, wearable EEG that can be deployed by non-EEG professionals
in an emergent setting, especially in community and rural hospitals that lack an EEG service. Rapid neuro
screening with EEG is critical for situations when patients are at risk of under-treatment if they are having
undetected subclinical or non-convulsive seizures, over-treatment if EEG is normal, and delayed treatment if
they are transported to a tertiary hospital for diagnosis.
WEARABLE SOLUTION
Epitel has developed Epilog, a wireless
wearable EEG sensor capable of transmitting
EEG to a recording, display, and review
platform called REMI (Remote EEG
Monitoring). Developed through R43/R44,
REMI synchronizes four Epilog sensors
placed by hospital Emergency Department
(ED) staff within minutes of patient arrival
who are suspect of seizures, prior to initial
treatment. REMI securely transmits the data Epilog sensors use a one-piece conductive and adhesive
to its cloud server where Persyst® software ‘sticker’ that attaches the sensor to the scalp below hairline.
processes the EEG in the real time for live
remote review by an epileptologist using Pesyst Mobile. As the final milestone in R44, Epitel cleared the REMI
platform with FDA (K203827) for use as a remote EEG screening tool for emergent care in EDs and intensive
care units, specifically targeting community and rural hospitals that do not have access to neurology or EEG.
REMI enables epileptologists to remotely direct time-sensitive treatment more accurately and faster in hospitals
that lack neurology or the capability to provide emergency EEG services.
COMMERCIALIZATION READINESS PILOT (CRP) Gaining market clearance through FDA is simply the first
step toward commercialization. We have identified 5 post-FDA development activities designed for translation.
 1. Demonstrate Clinical Utility through a multi-center, prospective, blinded, randomized clinical trial
 in children and adults
 2. Health Economics and Outcomes Research
 3. Intellectual Property Strategy assistance
 4. Manufacturing Optimization
 5. Go-to-Market Technical Assistance
The value of this CRP for Epitel is evidence for clinical utility, health economics modeling, market access, and
manufacturing optimization. The technical assistance provided through this CRP will de-risk our technology to
make the REMI platform attractive to venture capital investment prior to full commercialization.

## Key facts

- **NIH application ID:** 10805366
- **Project number:** 5SB1NS100235-07
- **Recipient organization:** EPITEL, INC.
- **Principal Investigator:** Mark J. Lehmkuhle
- **Activity code:** SB1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,199,931
- **Award type:** 5
- **Project period:** 2016-09-30 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10805366

## Citation

> US National Institutes of Health, RePORTER application 10805366, REMI Platform for Remote EEG Monitoring (5SB1NS100235-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10805366. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*